Theraclion S.A. (TCLIF) Stock Analysis

Theraclion S.A. (TCLIF) Healthcare & Pipeline Overview

Theraclion S.A., founded in 2004, develops and markets robotic echotherapy solutions using high-intensity focused ultrasound. Their flagship products, SONOVEIN and ECHOPULSE, offer non-invasive treatment options for varicose veins, thyroid nodules, and breast fibroadenomas, positioning them in the competitive medical device landscape.

What Is the Investment Thesis for TCLIF?

Theraclion operates in the niche market of non-invasive echotherapy, offering potential advantages over traditional surgical methods. The company's SONOVEIN and ECHOPULSE systems address specific medical needs with a focus on patient comfort and reduced recovery times. However, Theraclion's financial performance, indicated by a negative profit margin of -485.3% and a negative gross margin of -571.4%, raises concerns about its path to profitability. Growth catalysts include expanding the adoption of SONOVEIN for varicose vein treatment and increasing the utilization of ECHOPULSE for thyroid nodules and breast fibroadenomas. The company's success depends on demonstrating the clinical efficacy and cost-effectiveness of its echotherapy solutions compared to existing treatments. Key risks include competition from established medical device companies, regulatory hurdles, and the need for ongoing clinical trials to support product claims. The company's small market capitalization and OTC listing add further risk.

Based on FMP financials and quantitative analysis

TCLIF Key Highlights

Theraclion S.A. specializes in echotherapy solutions using high-intensity focused ultrasound.

• The company's product portfolio includes SONOVEIN for varicose veins and ECHOPULSE for thyroid nodules and breast fibroadenomas.
• Theraclion's market capitalization is approximately $0.00B.
• The company's P/E ratio is -3.95, indicating it is not currently profitable.
• Theraclion's profit margin is -485.3%, reflecting significant losses.

Who Are TCLIF's Competitors?

TCLIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TCLIF's Key Strengths?

Proprietary echotherapy technology.

• Non-invasive treatment solutions.
• Robotic precision.
• Established presence in a niche market.

What Are TCLIF's Weaknesses?

Negative profit margin and gross margin.

• Small market capitalization.
• Limited geographic reach.
• Dependence on a small number of products.

What Could Drive TCLIF Stock Higher?

Expansion of SONOVEIN into new markets and treatment centers.

• Clinical trials evaluating the efficacy of ECHOPULSE for new indications.
• Potential regulatory approvals for new products or expanded indications.
• Strategic partnerships with other medical device companies.
• Increasing awareness and adoption of echotherapy among physicians and patients.

What Are the Key Risks for TCLIF?

Financial-distress signal — its Altman Z-Score of -2.09 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established medical device companies.
• Regulatory hurdles and delays in product approvals.
• Need for ongoing clinical trials to support product claims.
• Negative profit margin and financial losses.
• Limited liquidity due to OTC listing.

What Are the Growth Opportunities for TCLIF?

• Expanding SONOVEIN adoption for varicose vein treatment: The market for varicose vein treatment is substantial, with a growing demand for non-invasive alternatives to traditional surgery. Theraclion's SONOVEIN system offers a potential solution for patients seeking a pain-free and scar-free treatment option. The company can drive growth by increasing awareness of SONOVEIN among physicians and patients, conducting clinical studies to demonstrate its efficacy, and expanding its distribution network.
• Increasing ECHOPULSE utilization for thyroid nodules: Thyroid nodules are a common condition, and ECHOPULSE offers a non-invasive treatment option for benign nodules. Theraclion can drive growth by educating endocrinologists and other healthcare professionals about the benefits of ECHOPULSE, conducting clinical trials to support its use, and expanding its market reach. The market for thyroid nodule treatment is expected to grow as the prevalence of thyroid disorders increases.
• Developing new applications for echotherapy: Theraclion's core technology has the potential to be applied to other medical conditions beyond varicose veins and thyroid nodules. The company can invest in research and development to explore new applications for echotherapy, such as the treatment of other types of benign tumors or vascular disorders. This could open up new markets and revenue streams for the company.
• Strategic partnerships and collaborations: Theraclion can accelerate its growth by forming strategic partnerships with other companies in the medical device industry. This could include collaborations with companies that have complementary technologies or distribution networks. Partnerships can help Theraclion expand its market reach, access new technologies, and share the costs of research and development.
• Geographic expansion: Theraclion's current market is primarily in Europe. The company can expand its geographic reach by entering new markets in Asia, North America, and other regions. This would require significant investment in sales and marketing, but it could also provide a substantial boost to the company's revenue.

What Are TCLIF's Competitive Advantages?

• Proprietary echotherapy technology using high-intensity focused ultrasound.
• Robotic solutions for precise and non-invasive treatment.
• Established presence in the niche market of echotherapy.
• Intellectual property protection for its technologies.

What Does TCLIF Do?

Theraclion S.A., established in 2004 and headquartered in Malakoff, France, is a medical device company focused on developing and commercializing echotherapy solutions. The company's core technology utilizes high-intensity focused ultrasound (HIFU) to provide non-invasive treatment options for various medical conditions. Theraclion's initial focus was on breast fibroadenomas, leading to the development of its ECHOPULSE system. Over time, the company expanded its product portfolio to address other therapeutic areas, including varicose veins with the introduction of SONOVEIN. ECHOPULSE is a robotic, non-invasive echotherapy platform designed for the treatment of thyroid nodules and breast fibroadenomas. The system uses real-time ultrasound imaging to precisely target and ablate the targeted tissue. SONOVEIN is a robotic solution for the non-invasive treatment of varicose veins. This system offers a pain-free alternative to traditional surgical methods. Theraclion also offers EPack, a disposable component installed on the device before treatment, designed to protect the patient's skin and optimize image quality during procedures. Theraclion's products are marketed to hospitals, clinics, and specialized medical centers. The company aims to establish echotherapy as a standard of care for the treatment of benign tumors and vascular conditions, offering patients a less invasive and potentially more comfortable treatment experience.

What Products and Services Does TCLIF Offer?

• Develops echotherapy solutions using high-intensity focused ultrasound.
• Offers SONOVEIN for non-invasive treatment of varicose veins.
• Provides ECHOPULSE for non-invasive treatment of thyroid nodules and breast fibroadenomas.
• Manufactures and sells EPack, a disposable component for their devices.
• Markets their products to hospitals, clinics, and specialized medical centers.
• Focuses on providing less invasive treatment options for patients.

How Does TCLIF Make Money?

• Sells echotherapy systems (SONOVEIN and ECHOPULSE) to medical facilities.
• Generates revenue from the sale of disposable components (EPack).
• Provides training and support services to customers.
• Potentially generates revenue from service and maintenance contracts.

What Industry Does TCLIF Operate In?

The medical device industry is characterized by innovation, technological advancements, and stringent regulatory requirements. The market for non-invasive therapies is growing, driven by patient demand for less painful and faster recovery options. Theraclion operates in this space, competing with companies offering traditional surgical procedures and other non-invasive modalities. The industry is subject to intense competition, with established players and emerging startups vying for market share. The success of companies like Theraclion depends on their ability to demonstrate the clinical and economic value of their technologies.

Who Are TCLIF's Key Customers?

• Hospitals
• Clinics
• Specialized medical centers
• Physicians specializing in vascular surgery, endocrinology, and breast surgery

Company Profile

Theraclion S.A. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Malakoff, FR. The company is led by CEO Martin Deterre. TCLIF has traded publicly since 2019.

Theraclion S.A. (TCLIF) Valuation Context

Valued at $38.9M, TCLIF is classified as a micro-cap stock.

Return on equity for Theraclion S.A. stands at 222.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -45.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -7.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.21 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -15.0%, the inverse of the P/E and a quick read on earnings relative to price.

Theraclion S.A.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -2.09 places it in the distress zone, a signal of elevated financial risk.

TCLIF Financials

TCLIF Latest News

No recent news available for TCLIF.

TCLIF Analyst Consensus

TCLIF MoonshotScore

TCLIF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources